contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vitrolife-ab-publ-interim-report-q2-2022-together-for-successful-growth

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vitrolife is a global provider of solutions in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics in enhancing their practice as well as the outcome of a patient’s fertility treatment. Vitrolife´s products and services are available globally, and the company is headquartered in Gothenburg, Sweden.

Vitrolife

Second quarterSales of SEK 829 (382) million, corresponding to an increase of 117% in SEK, whereof currency effect 18%, acquired growth 80% and organic growth 18%.Consumables increased sales...

Second quarter<ul><li>Sales of SEK 829 (382) million, corresponding to an increase of 117% in SEK, whereof currency effect 18%, acquired growth 80% and organic growth 18%.</li><li>Consumables increased sales by 24% in SEK, Technologies by 37% in SEK, and Genetic Services contributed sales of SEK 341 million.</li><li>Strong growth in all market regions. Americas 241%, EMEA 53%, Japan Pacific 85% and Asia 73% in local currencies.</li><li>Operating income before depreciation and amortisation (EBITDA) was SEK 273 (134) million, corresponding to a margin of 32.9% (35.2%). EBITDA per share increased by 63%.</li><li>Net income was SEK 130 (86) million, resulting in earnings per share of SEK 0.96 (0.79).</li></ul>Pro forma<ul><li>Sales, adjusted for business related to Covid-19 tests, increased by 24% in SEK, and 14% in local currencies.</li><li>EBITDA margin of 32.9% (32.8%).</li></ul>First half year<ul><li>Sales of SEK 1,581 (761) million, corresponding to an increase of 108% in SEK, whereof currency effect 16%, acquired growth 77% and organic growth 15%.</li><li>Consumables increased sales by 25% in SEK, Technologies by 18% in SEK, and Genetic Services contributed sales of SEK 645 million.</li><li>Strong growth in all market regions. Americas 247%, EMEA 68%, Japan Pacific 48% and Asia 45% in local currencies.</li><li>Operating income before depreciation and amortisation (EBITDA) was SEK 501 (297) million, corresponding to a margin of 31.7% (39.1%). EBITDA per share increased 35%.</li><li>Net income was SEK 213 (205) million, resulting in earnings per share of SEK 1.56 (1.88).</li></ul>Pro forma<ul><li>Sales, adjusted for business related to Covid-19 tests, increased by 21% in SEK, and 12% in local currencies.&nbsp;</li><li>EBITDA margin of 31.7% (33.6%).</li></ul><p>Gothenburg, July 15, 2022<br>VITROLIFE AB (publ)<br>Thomas Axelsson, CEO</p>